Lilly Projects 2024 Revenue Miss as Zepbound, Mounjaro Disappoint
The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, sent Eli Lilly’s shares cratering by as much as 8% Tuesday, even as the company forecasted robust 2025 revenue.
Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...
Shares of Wells Fargo rose 3.9% after the San Francisco bank’s fourth-quarter profit of $1.43 a share beat expectations of $1 ...
Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant ...
Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...
Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion ...
The S&P 500 added 0.1% on Tuesday, Jan. 14, as tame wholesale inflation data provided a positive signal ahead of Wednesday's ...
JPMorgan analyst Chris Schott says Eli Lilly’s Q4 miss represents a buying opportunity as the company is positioned for strong growth in 2025. The company’s 2025 sales guidanc ...
Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with ...
Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...
Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback